NCT05394064View on ClinicalTrials.gov

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2029

Conditions
AMNAMN Gene MutationX-ALD
Interventions
GENETIC

SBT101

SBT101 Treatment

PROCEDURE

Imitation Procedure

Procedure that mimics SBT101 infusion, but contains no drug administered

Trial Locations (2)

01655

University of Massachusetts Chan Medical School, Worcester

Unknown

Amsterdam UMC, Amsterdam

All Listed Sponsors
lead

SwanBio Therapeutics, Inc.

INDUSTRY

NCT05394064 - A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) | Biotech Hunter | Biotech Hunter